A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory or Intolerant to BCG Therapy.
|Eligibility criteria|| |
|Study details|| |
The treatment is immunotherapy 3 weekly. While on treatment there will be regular blood tests, urine tests, cystoscopies, and scans to monitor progress. At completion of treatment the study will continue to follow your progress.
|Further information|| |
For more information regarding this clinical trial click here.
North Shore NSW